OPIOIDS

KEY POINTS

- Opioid therapy is not indicated for the long-term management of chronic non-cancer pain.
- Long term opioid use is associated with an average 0.69 point reduction in a 10 point visual analog score for pain. Long term opioid use is associated with a 2 point improvement in a 100 point physical functioning scale.
- Multidisciplinary pain management programs utilising psychology, exercise and functional-based outcomes result in better quality of life and better pain management than use of opioids.
- Tolerance to the analgesic effects of opioids develops in almost all people with long term use.
- Long term opioid use is associated with serious adverse hormonal and psychological effects as well as increased mortality.
- Concurrent benzodiazepine use confers a higher risk of death from drug overdose with opioids.
- People with chronic non-cancer pain taking 100 oral morphine milligram equivalents or more should have their opioids decreased.
- Patient education is essential to successfully taper opioids.

CONTEXT

This guide considers the use of opioid medications in the treatment of chronic non-cancer pain.

RECOMMENDED DEPRESCRIBING STRATEGY

- Deprescribing or tapering of opioids is more likely to be successful when the person is aware of the issues with long term opioid use.
- A number of consumer resources are available to assist with management of chronic pain. A good quality Australian resource is available through the Hunter Integrated Pain Service at www.hnehealth.nsw.gov.au/pain/. There are multiple sections written for consumers on understanding chronic pain, and understanding five key treatment areas: Biomedical, Mindbody, Connection, Activity and Nutrition.
- For People with chronic non-cancer pain taking long term oral opioids:
  - Current evidence strongly favours opioid deprescribing in patients taking more than 100 oral morphine milligram equivalents daily. This will usually include dose reduction with or without opioid rotation accompanied by appropriate education and information.
  - Patients taking between 50 and 100 oral morphine milligram equivalents should be considered for opioid tapering, depending on individual circumstances (adverse effects, efficacy, risk of falls, etc).
- People with chronic non-cancer pain taking any dose of opioids should be closely monitored and those whose pain control is stable may be considered for dose reduction or cessation of opioids.

BENEFIT VERSUS HARM

<table>
<thead>
<tr>
<th>Main Benefits</th>
<th>Increased Benefit</th>
<th>Reduced Harms</th>
<th>Main Harms</th>
<th>Decreased Harms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short term pain relief</td>
<td>Short term use for acute pain</td>
<td>Functionally independent and robust condition</td>
<td>Mortality, Respiratory failure, Falls, Fractures, Poor sleep, Endocrine/Immune issues</td>
<td>Presence of benzodiazepines or other respiratory depressants</td>
</tr>
<tr>
<td>Oral Morphine Milligram equivalent of 100mg or more</td>
<td>Oral Morphine Milligram equivalent of 50mg or more in frail elderly patients</td>
<td>Low body weight</td>
<td>Frailty</td>
<td></td>
</tr>
</tbody>
</table>
Opioids are commonly used to treat acute and malignant pain and can be used in palliative care and in the treatment of opioid addiction. This deprescribing guide applies to the use of opioids in chronic non-cancer pain.

Over the last couple of decades, opioids have increasingly been used in the management of persistent pain. **Opioid therapy is not indicated for the long-term management of chronic non-cancer pain based on current evidence.** The limited evidence supporting long term efficacy is weak and based on non-blinded, industry-sponsored trials with significant potential for reporting bias. This is outweighed by a consistent body of evidence demonstrating lack of long term analgesic efficacy, lack of improvement in function or quality of life and greater risk of harm to both individuals and society than previously recognised. Significant increases in the use of opioid medications for persistent pain have been accompanied by increases in opioid overdoses, abuse, addiction and diversion, as well as uncertainty about long-term efficacy.2,3,4,5,6

Opioids are playing a diminishing role in the management of chronic pain. Multidisciplinary pain management programs utilising psychology, exercise and functional-based outcomes result in better quality of life and better pain management than use of opioids.

**OPIOID USE IN AUSTRALIA**

In 2016–17, 15.4 million opioid prescriptions were dispensed under the Pharmaceutical Benefits Scheme.7 Oxycodone was the most commonly dispensed opioid, with 5.7 million prescriptions dispensed (a rate of 23,515 prescriptions dispensed per 100,000 population), followed by codeine (3.7 million prescriptions, or a rate of 15,216 prescriptions dispensed per 100,000 population) and tramadol (2.7 million prescriptions, or a rate of 11,147 prescriptions dispensed per 100,000 population). (see Figure 1).

Each opioid has different potency compared to morphine and their relative oral Morphine Equivalent (OME) dose can be estimated. For all opioids combined, there were 1,082 OME mg per 1,000 population, per day, dispensed in 2016–17. This equates to each person in Australia taking over one milligram of morphine daily. The most-used opioids, as measured by the rate of OME, were oxycodone (34% of all opioid OME), tramadol (17%) and fentanyl (11%).

![Figure 1: Number of prescriptions dispensed and rate of OME, by type and strength of opioid, 2016–17.](image-url)
In chronic non-cancer pain, systematic reviews of randomised controlled trials (RCTs) demonstrate modest, short-term analgesic benefit. However, these research findings cannot be extrapolated into clinical practice given the short duration of therapy (average trial duration was 5 weeks with a range of 1 to 16 weeks). Tolerance and opioid-induced hyperalgesia are major limiting factors in regard to longer term use.

A systematic review of opioid response after 6 months of therapy in 25 non-randomised case series shows weak evidence of modest analgesic benefit and inconclusive data in regard to improvement in physical function and quality of life. A Cochrane review in 2014 examined the evidence relating to opioids for osteoarthritis pain. Opioids were more beneficial in pain reduction than control interventions (the difference in pain scores was only 0.7 cm on a 10-cm visual analogue scale). Improvement of function with opioids was also only minimal (a difference in function scores of only 0.6 units on a disability scale from 0 to 10). Against these modest benefits, side effects for opioids were more common (22% vs 15%; NNH=14).

More recently, a systematic review of the efficacy of opioids for low back pain reviewed 20 randomised controlled trials. In trials of short term effects of opioids they found modest short term benefit, but evidence of long-term benefit was lacking. Other reviews of opioid and non-opioid pharmacological therapies for low back pain also found only small, short term effects for opioids.

Chou et al recently reviewed all literature available 4209 papers in order to evaluate evidence for effectiveness and harms of long term (greater than 3 months) opioid therapy for chronic pain in adults. Despite this extensive search, they were unable to find any studies that evaluated long-term outcomes of opioid use in relation to pain, function or quality of life. These authors support the view of a previous update of a Cochrane review of the use of opioids for chronic low back pain, which concluded, “We have no information from randomized trials supporting the efficacy and safety of opioids used for more than 4 months.”

A position paper from the American Academy of Neurology further supports the limited evidence in long-term settings and states that the risks of chronic opioid therapy for some chronic conditions such as low back pain, headache and fibromyalgia are likely to outweigh the benefit.
PRESCRIPTION OPIOID USE AND MORTALITY

In the 11 years from 2001 to 2011 there were 806 oxycodone-related deaths in Australia, of which 40% were people taking legitimate prescriptions for oxycodone as directed. It is interesting to note that there was a greater than a five fold increase in defined daily dose of oxycodone in the 11 year period. There is a close correlation between the average daily dose of oxycodone used and oxycodone-related deaths (see Figure 3).

Caution with Benzodiazepines

Most often, the deaths were caused by combinations of agents (often other centrally acting agents involved) and the deaths were not intentional. The most commonly co-administered drugs were benzodiazepines, alcohol and other opioids. Coadministration of benzodiazepines, in particular, increases the risk of overdose mortality. A history of benzodiazepine use more than doubled risk of mortality and current benzodiazepine use increased death from drug overdose almost four fold (see Figure 4).

TOLERANCE

Opioid tolerance – a need for increased doses to achieve the desired effect – has been demonstrated in animal models and is seen in humans in both short term and long-term studies of opioids in humans. In a prescription database study of six years of data from Norway, dose increases of 50% or more were reported in 35% of opioid users. A similar insurance database study in the USA found that over 50% of patients who took opioids for 90 days were still taking them 3-5 years later. Factors strongly associated with continuation of opioids were intermittent prior opioid exposure, daily opioid dose over 120 oral morphine milligram equivalents and possible opioid misuse.

There is only limited cross-tolerance between opioids as a result of differing characteristics and responses of opioid receptors. As a result, rotation of opioids, to a net lower dose, can be a useful strategy for improving analgesia.

OPIOID-INDUCED HYPERALGESIA (OIH)

Excessive opioid exposure may also produce a paradoxical increase in pain sensitivity manifested as hyperalgesia (exacerbated painful response to noxious stimulation) and/or allostynia (painful response to non-noxious stimulation). This opioid-induced hyperalgesia has been demonstrated in both short term and long-term use of opioids. The mechanism of this effect is still being elucidated, but central pain sensitisation, NMDA receptor activity and spinal dynorphin release have all been implicated as factors.

Opioid-induced hyperalgesia should be suspected when the treatment effect wanes in the absence of disease progression, particularly in the context of unexplained or increased pain. Often, hyperalgesia presents as a change in the nature of the pain, with neuropathic pain-like elements. Opioid dose reduction, opioid rotation and NMDA receptor modulators are suggested treatments.

Figure 3: Oxycodone related deaths in Australia (DDD = Defined Daily Dose)

Figure 4: Death rates for drug overdose by benzodiazepine prescription history and daily opioid dose (DDD = Defined Daily Dose)
OPIOID DEPENDENCE, MISUSE AND ADDICTION
Prolonged use of opioids leads to many patients developing a physical dependence which can occur without an opioid use disorder. In these patients, cessation causes an unpleasant withdrawal syndrome, which may include both physical and psychological features. Opioid dependence may emerge at different times for different patients and withdrawal symptoms may occur cessation is sudden.

Problem use of prescription opioids ranges from overuse (occasionally using more than prescribed), to misuse (use that is potentially harmful or dangerous), to opioid use disorder (or addiction). Addiction is characterized by repeated compulsive drug seeking (psychological dependence) and continued use despite adverse social, psychological, or physical consequences. Physical dependence can occur in patients receiving long term opioids with or without an opioid use disorder.

FALLS AND FRACTURE RISK
A number of adverse opioid effects, such as sedation and dizziness, can increase the propensity to falls due to central nervous system effects. Opioids may also decrease bone mineral density by impairing the production of endogenous sex steroids, and the effect on bone metabolism may directly weaken bone structure. As elderly persons are at increased risk of developing osteoporosis and pain, the opioids used to treat pain in this population may increase the risk of subsequent fractures.

A recent meta analysis of eight studies found that opioids increase the risk of overall fractures by 88% and of hip fractures by 100%.

The evidence indicates that an initial prescription for opioids increases the risk of fracture more so than longer term use. In a population study in the United Kingdom, patients with their first opioid prescription had a higher hip fracture risk than patients who had multiple prescriptions.

ENDOCRINE/HORMONAL ADVERSE EFFECTS
Opioids may affect the hypothalamic-pituitary-adrenal axis, and lead to opioid induced androgen deficiency (OPIAD) with reduced testosterone production. This may lead to osteoporosis and immune suppression in men, with recent data suggesting that up to five million men have OPIAD in the USA. Among men with back pain, on a daily dose of at least 120 oral morphine milligram equivalents long term, 19% used drugs for erectile dysfunction or testosterone replacement compared to only 7% of patients with pain but no opioids.

Chronic opioid use can lead to amenorrhea or oligomenorrhea in premenopausal women due to a reduction in both testosterone and estradiol.

LESS SERIOUS ADVERSE EFFECTS
Opioids are associated with a number of common, short-term, constitutional side effects, of which most cause no permanent harm and some improve with time (see Figure 1). An exception is constipation, which often requires management for the duration of opioid therapy.
A number of studies have shown that opioid tapering can result in improvements in pain management and a reduction in adverse effects. These studies suggest that many patients with persistent pain can achieve favourable pain and function outcomes after stopping or reducing opioids in multidisciplinary interventions.

The Center for Disease Control in the USA has released guidelines for prescribing opioids for chronic pain. One of their recommendations is that additional precautions should be implemented when dosage is increased to more than 50 oral morphine milligram equivalents (oMME), and that doses above 90 morphine milligram equivalents should be avoided. The Hunter Integrated Pain Service in Australia recommends an opioid dose limit of 100 oMME. The Faculty of Pain Medicine of the Australian New Zealand College of Anaesthetists has released recommendations regarding the use of opioid analgesics in patients with chronic non-cancer pain. A phone or device-based application is also available to assist in opioid conversion that has been prepared by the ANZCA (Opioid Calculator FPM ANZCA).

The tables below show the approximate morphine milligram equivalents of some common opioids and the doses that match the doses identified in the ANZCA opioid conversion application for caution (orange) and avoidance (red).

**FACTORS TO CONSIDER**

Opioids are playing a diminishing role in the management of chronic pain. Multidisciplinary pain management programs utilising psychology, exercise and functional-based outcomes result in better quality of life than use of opioids. As such, many patients taking long term (greater than 6 months) opioid therapy for non-cancer chronic pain may be considered for dose reduction and/or cessation.

The following factors may be an indication for opioid dose tapering or cessation:
- Patients with a lack of demonstrable clinical effectiveness
- The existence of severe unmanageable adverse effects
- Patients who are stable and have a decreased level of pain
- Evidence of misuse, illegal or unsafe behaviours

If patients have a desire to discontinue their opioid therapy, then support and education will assist in achieving this goal.

**AGAINST DEPRESCRIBING**

- Patients who require analgesia for serious acute pain (e.g. fractures) may require short term opioid therapy for several weeks.
- Opioid therapy can usually be ceased within one week of surgery or injury. In more complex cases, opioids should be weaned and ceased within 90 days, at most.

### Table 2: oral Morphine Milligram Equivalents of common opioids

<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>EXAMPLE OF A TYPICAL DOSE</th>
<th>ORAL MORPHINE MILLIGRAM EQUIVALENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine oral</td>
<td>30mg</td>
<td>4</td>
</tr>
<tr>
<td>Fentanyl transdermal</td>
<td>12mcg/hr 36/day</td>
<td></td>
</tr>
<tr>
<td>Hydromorphone oral</td>
<td>8mg</td>
<td>40</td>
</tr>
<tr>
<td>Morphine oral</td>
<td>10mg</td>
<td>10</td>
</tr>
<tr>
<td>Norspan transdermal</td>
<td>5mcg/hr 10/day</td>
<td></td>
</tr>
<tr>
<td>Oxycodone oral</td>
<td>10mg</td>
<td>15</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>100mg</td>
<td>20</td>
</tr>
</tbody>
</table>

### Table 3: oral Morphine Milligram Equivalents of doses for caution and avoidance for common opioids

<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>APPROXIMATE DOSE FOR CONCERN (50 OMME)</th>
<th>APPROXIMATE DOSE TO BE AVOIDED (100 OMME)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine oral</td>
<td>320mg/day</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Fentanyl transdermal</td>
<td>25mcg/hour 33mcg/hr</td>
<td></td>
</tr>
<tr>
<td>Hydromorphone oral</td>
<td>10mg/day 20mg/day</td>
<td></td>
</tr>
<tr>
<td>Morphine oral</td>
<td>50mg/day 100mg/day</td>
<td></td>
</tr>
<tr>
<td>Norspan transdermal</td>
<td>25mcg/hour 50mcg/hr</td>
<td></td>
</tr>
<tr>
<td>Oxycodone oral</td>
<td>30mg/day 65mg/day</td>
<td></td>
</tr>
<tr>
<td>Tapentadol</td>
<td>125mg/day 250mg/day</td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>250mg/day 500mg/day</td>
<td></td>
</tr>
</tbody>
</table>
Patient education is essential to successfully taper opioids. Clear written and verbal instructions should be provided to patients and families to educate them about the tapering protocol that will minimise withdrawal symptoms. Opioid withdrawal can develop within hours of drug cessation. While the effects of withdrawal are unlikely to be life threatening in patients without significant comorbidities, it can be quite uncomfortable. Signs and symptoms of withdrawal may include:

- gastrointestinal symptoms (e.g., abdominal cramping, nausea, vomiting, diarrhoea)
- musculoskeletal symptoms (e.g., myalgias, arthralgias, muscle spasms)
- anorexia, yawning, lacrimation, salivation, rhinorrhea, piloerection, insomnia, anxiety, irritability, dysphoria
- manifestations of sympathetic hyperactivity such as diaphoresis, tachycardia, fever, mydriasis or mildly elevated blood pressures
- In people who have significant comorbidities, withdrawal should be medically managed.

GENERAL APPROACH TO OPIOID TAPERING WITH PATIENTS

A motivational approach may be helpful as this elicits the patient’s own reasons for change or intrinsic motivation and is likely to be much more effective. Examples of ways to start the conversation include:

- Ask about the upsides and downsides from the patient’s perspective. “Tell me about how your opioids help you now, compared to when you started them.” Reflect on any responses and emotions.

- Listen carefully, and then link together pros and cons (if any). “So on the one hand, you still are not able to do all the things you want to do inside and outside of the house and you are worried about all the risks related to opioids, but you are scared about withdrawal and not having anything to manage your pain.”

- Try and then steer the conversation to strategies that might tackle the issues as identified by the patient.

The rate of tapering is dependent on the clinical context (duration of treatment and the reason for tapering) and the aim is to limit withdrawal symptoms and avoid escalation of patient distress. Guidelines have been published in Canada.40

LONG TERM TREATMENT WITHOUT CLEAR BENEFIT

In situations where long term opioid therapy has been maintained (at times for many years) without meaningful improvement in function, the desired outcome is weaning to cessation if possible. One practical strategy is to reduce the daily opioid dose each month by 10-25% of the starting dose. This brings cessation in 3-9 months.

END OF AGREED TRIAL OR FAILURE OF TREATMENT

If weaning is required after a shorter period of opioid therapy, such as after failure to achieve the goals of an opioid trial, or after a negotiated treatment phase for acute pain, then a faster rate of weaning is generally appropriate. One option is a step-wise reduction of the daily opioid dose each week by 10-25% of the starting dose.

SIGNIFICANT ADVERSE EFFECTS

If weaning is required in response to significant adverse effects or opioid misuse, then daily step-wise reduction may be more appropriate. Alternatively, immediate opioid cessation and pharmacological treatment of withdrawal symptoms can be considered.

PREVIOUS FAILED ATTEMPTS AT TAPERING

If a previous attempt at opioid weaning has proven unsuccessful, then the rate may be slowed. This can be achieved by reducing the size of the dose reduction each month and/or by increasing the time spent at each dose level (e.g. 2 or 3 months between reductions).

REFERENCES


REFERENCES (CONT.)